AnPac Bio-Medical Science Co., Ltd.
Anpac Bio is a biotechnology company focusing on early cancer screening, detection, and marketing a suite of cancer detection tests, including CDA (Cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented Cancer Differentiation Analysis (CDA) technology and proprietary cancer-detection device.
Location of Key Operations
Ernst & Young LLP
IPO (January 10, 2020)
British Virgin Islands
Lishui, Zhejiang, China
Tina Xiao, Ascent Investor Relations LLC
August 23, 2021: AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration (NMPA) for Registration Testing of Its Multi-Cancer CDA Device | AnPac Bio
May 25, 2021: AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database | AnPac Bio